SCHEMBL5435705

SCHEMBL5435705

COc1cccc(-c2ccc(=O)n(Cc3ccc(Cl)cc3)c2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.58
GRM2 Q14416 1/20 0.51
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
ALDH1A3 P47895 1/20 0.48
MAPT P10636 3/20 0.48
TP53 P04637 2/20 0.48
LMNA P02545 1/20 0.48
HTR1A P08908 1/20 0.47
ADRA2A P08913 1/20 0.47
ADRA2B P18089 1/20 0.47
ADRA2C P18825 1/20 0.47
DRD4 P21917 1/20 0.47
SLC6A2 P23975 1/20 0.47
HTR2C P28335 1/20 0.47
SLC6A4 P31645 1/20 0.47
OPRK1 P41145 1/20 0.47
HTR2B P41595 1/20 0.47
HTR5A P47898 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5435549 0.90 BRD4 (0.60) BRD4GRM2MAPTTP53LMNA
SCHEMBL5447856 0.88 SDHB (0.48) BRD4KDM4EALDH1A1SMN1; SMN2MAPT
SCHEMBL5441324 0.87 BRD4 (0.54) BRD4GRM2SMN1; SMN2MAPTTP53
SCHEMBL5435867 0.85 SDHB (0.50) GRM2ALDH1A1SMN1; SMN2MAPTTP53
SCHEMBL5439789 0.84 MKNK1 (0.47) BRD4ALDH1A1SMN1; SMN2MAPTTP53
SCHEMBL5184783 0.82 MAPT (0.54) KDM4EALDH1A1SMN1; SMN2MAPTTP53
SCHEMBL5443007 0.81 MKNK1 (0.48) ALDH1A1SMN1; SMN2MAPTIDH1SDHB
SCHEMBL5435624 0.81 MAPT (0.61) BRD4KDM4EALDH1A1MAPTTP53
SCHEMBL5434488 0.80 MAPT (0.65) ALDH1A1MAPTTP53LMNASDHB
SCHEMBL5194802 0.80 MAPT (0.61) ALDH1A1MAPTTP53LMNASDHB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130109652-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS ADDEX PHARMACEUTICALS S.A. (CH) 2013-05-02 US claimed
US-20130109652-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS ADDEX PHARMACEUTICALS S.A. (CH) 2013-05-02 US disclosed
US-8399493-B2 Pyridinone derivatives and their use as positive allosteric modulators of mGluR2-receptors Janssen Pharmaceuticals, Inc. (US) 2013-03-19 US disclosed
US-20070213323-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS Janssen Pharmaceuticals, Inc. 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213323-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS GRM2, GRM1, GRM3 BRD4 1456/4885GRM2 1/4885KDM4E 1936/4885
US-20130109652-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS GRM2, GRM1, GRIA2 BRD4 1140/4885GRM2 1/4885KDM4E 1707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.